All In Biotech

Drug Trial Radar · NCT03639844

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders

Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

No longer available

Status

No longer available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 21, 2018

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 3 months, up to 21 years

Summary

As written by the sponsor on the registry.

Providing access of BPX-501 gene modified T cells and rimiducid to pediatric patients who do not meet the eligibility criteria of the BP-U-004 study.

Conditions

  • Hurler Syndrome
  • Inherited Metabolic Disorder
  • Lysosomal Storage Disorder
  • Metachromatic Leukodystrophy
  • Inborn Errors of Metabolism

Interventions

  • rivogenlecleucelBiological

    BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.

  • rimiducidDrug

    Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Stanford University; Division of Pediatric Stem Cell Transplant & Regenerative Medicine

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.